Aurobindo Pharma is currently trading at Rs. 782.60, up by 3.60 points or 0.46% from its previous closing of Rs. 779.00 on the BSE.
The scrip opened at Rs. 784.70 and has touched a high and low of Rs. 787.00 and Rs. 778.40 respectively. So far 23150 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 891.50 on 30-Dec-2015 and a 52 week low of Rs. 582.00 on 25-Feb-2016.
Last one week high and low of the scrip stood at Rs. 805.15 and Rs. 767.20 respectively. The current market cap of the company is Rs. 45889.00 crore.
The promoters holding in the company stood at 53.79%, while institutions and non-institutions held 34.08% and 12.13% respectively.
Aurobindo Pharma is planning to launch 19 approved products that have an addressable market of $6.8 billion in the US in the next three quarters. Moreover, the company has another 22 targeted 'action dates through the end of the financial year' although it does not 'anticipate all those will be final approvals but a significant number will be'.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.